Stop wondering if your investment will pay off and start your journey with biological certainty. Before you commit to the high cost of GLP-1 “jabs,” our Pre-Treatment Determination Assessment uses advanced precision medicine to predict exactly how your body will respond to medications like Ozempic, Wegovy, or Mounjaro.
By bridging the gap between your current metabolic health via our Diabetes Risk Clinical Scale and your unique genetic blueprint targeting the key specific markers, we calculate your personal Therapeutic Benefit Index.
This proprietary algorithm identifies whether you are a “High-Response Candidate” or one of the 14% of biological non-responders—saving you months of potential frustration and thousands of pounds in ineffective treatment.
Don’t leave your weight loss to chance; get the data-driven roadmap your metabolism deserves.
Stop wondering if your investment will pay off and start your journey with biological certainty. Before you commit to the high cost of GLP-1 “jabs,” our Pre-Treatment Determination Assessment uses advanced precision medicine to predict exactly how your body will respond to medications like Ozempic, Wegovy, or Mounjaro.
✓ DNA Testing – Identify specific gene markers
✓ Clinical Risk Assessment – based on lifestyle, anthropometric, and clinical factors
✓ Secure Portal – Access questionnaires & reports online
✓ Custom Reports – Tailored to your body & lifestyle
✓ Risk Reduction Plan – Personalized lifestyle guidance
It’s for everyone.
It’s for you, if you are thinking about taking one of the various weightloss jabs out there but are uncertain if you will benefit then this is the test for you.
Whatever your age, health or lifestyle, your Optimal Health Weightloss Report will answer questions you have about your future wellbeing.
While lifestyle factors—poor diet, inactivity, and chronic stress—contribute significantly to weight gain, genetic predisposition determines susceptibility to obesity and insulin resistance. Excess weight, particularly visceral fat, triggers inflammation and hormonal imbalances that impair blood sugar regulation, creating diabetes risk. These medications mimic natural hormones to regulate appetite and enhance insulin secretion, delivering substantial weight loss (6-20% of body weight) while reducing diabetes and cardiovascular risks, especially when combined with healthy lifestyle changes.
You are unique, so learn what healthy living means for you. You will receive personalised expert recommendationalso know as our Pre-Treatment Determination.
The Optimal Health Weightloss Test acts as a “Gatekeeper” or “Precision Filter” to identify if you are a high-value candidate versus if you may be a biological non-responder before a single dose is administered.
Your personalised Optimal Health Weightloss Test will provide a determination whether you are a High Benefit, Moderate Benefit or aLikely Non-Responder.
*NOTE*
Although our results are based on emprical research they are provided for informational purposes only. For medical advice or diagnosis it is important that you consult a professional, which you wil;l have to do before undertaking any weight loss programme that includes the jabs.
Although our results are based on emprical research they are provided for informational purposes only. For medical advice or diagnosis it is important that you consult a professional, which you will have to do before undertaking any weight loss programme that includes the jabs.
The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, represents a breakthrough in addressing obesity and type 2 diabetes—conditions driven by a complex interplay of genetic predisposition and lifestyle factors. Recent research has revealed that genetic variants in the GLP1R and GIPR genes significantly influence individual responses to these medications, with approximately one in ten people carrying genetic variations that may reduce drug effectiveness or increase side effect risks. While lifestyle factors such as poor diet, sedentary behavior, and chronic stress contribute substantially to weight gain and metabolic dysfunction, genetic susceptibility plays a crucial role in determining who develops obesity and insulin resistance. The connection between obesity and diabetes is particularly significant, as excess weight—especially visceral fat—triggers inflammatory processes and hormonal imbalances that impair the body’s ability to regulate blood sugar effectively. GLP-1 medications work by mimicking natural hormones that regulate appetite, slow gastric emptying, and enhance insulin secretion, offering substantial weight loss (ranging from 6% to over 20% of body weight) while simultaneously reducing diabetes risk and cardiovascular events, particularly when combined with healthy lifestyle modifications. This dual benefit makes these medications especially valuable for individuals facing both genetic and lifestyle-related metabolic challenges.
The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide and tirzepatide, represents a breakthrough in addressing obesity and type 2 diabetes—conditions driven by a complex interplay of genetic predisposition and lifestyle factors. Recent research has revealed that genetic variants in the GLP1R and GIPR genes significantly influence individual responses to these medications, with approximately one in ten people carrying genetic variations that may reduce drug effectiveness or increase side effect risks. While lifestyle factors such as poor diet, sedentary behavior, and chronic stress contribute substantially to weight gain and metabolic dysfunction, genetic susceptibility plays a crucial role in determining who develops obesity and insulin resistance. The connection between obesity and diabetes is particularly significant, as excess weight—especially visceral fat—triggers inflammatory processes and hormonal imbalances that impair the body’s ability to regulate blood sugar effectively. GLP-1 medications work by mimicking natural hormones that regulate appetite, slow gastric emptying, and enhance insulin secretion, offering substantial weight loss (ranging from 6% to over 20% of body weight) while simultaneously reducing diabetes risk and cardiovascular events, particularly when combined with healthy lifestyle modifications. This dual benefit makes these medications especially valuable for individuals facing both genetic and lifestyle-related metabolic challenges.
Your personal data is protected and anonymised in the analysis process – our laboratories only know you by a reference number. Our customer records are held on a secure server, and we follow the Information Commissioner’s GDPR rules for keeping your data safe.
We never give your data to third parties or use your data in any way other than to produce your Optimal Health Report.
For further information, see our Privacy Policy
